What dose of Wegovy is effective — and when does it start working?

The misconception: that a low dose means the medicine isn't working

A lot of people starting Wegovy assume that if they are not losing substantial weight in the first four weeks, something is wrong. That feeling is understandable. You have waited, you have paid, and the scales have barely moved. But the 0.25mg starting dose was never designed to drive weight loss, its job is to let your body adjust to semaglutide before the dose climbs. Nausea, fatigue and gut discomfort are most common early on, and the gentle start reduces how severe those tend to be. If you are wondering whether 0.25mg semaglutide is doing anything useful at this stage, the short answer is that it is preparing your body rather than targeting the scales. Once that framing settles in, the impatience usually eases too.

The same logic applies at 0.5mg and 1.0mg. These are stepping stones, not endpoints. Whether 0.5mg produces any measurable weight loss varies between people, but it is not the dose the trial evidence was built around. Expecting 15% weight loss at 0.5mg sets up an unfair comparison. The full Wegovy dose schedule is worth reading before you start, so the journey makes sense from week one.

Your prescriber will review progress and tolerability before each increase. Rushing the schedule is not an option, and slowing it down because of side effects is a legitimate clinical decision, not a failure.

Where the clinical evidence actually sits

The headline figure for Wegovy comes from the STEP 1 trial: roughly 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, published in the New England Journal of Medicine. That is an average across the trial population, some people lost considerably more, others less. No trial result should be read as a personal prediction.

In 2026 the picture shifted again. The MHRA approved a higher 7.2mg maintenance dose for adults with a BMI of 30 or above. Early data suggest around 20.7% average weight loss at this dose over 72 weeks, narrowing the gap with tirzepatide's trial results. The dedicated single-dose 7.2mg pen was confirmed by the MHRA on 14 April 2026. Whether that dose is clinically appropriate for any individual is a prescriber's call, availability at consultation is the point to raise it.

For a broader look at how Wegovy compares across the range, the evidence on which Wegovy dose produces the most weight loss goes into more detail on the dose-response relationship.

What actually determines how effective your dose is

Dose is one variable. The others matter just as much. Semaglutide works by activating GLP-1 receptors involved in appetite regulation and gastric emptying, it creates the biological conditions for eating less. But the reduction in calories still has to happen. The NHS guidance on weight-management injections is clear that these medicines work alongside a reduced-calorie diet and increased activity, not instead of them.

Sleep, stress, how consistently you take your dose, and whether you have conditions that affect metabolism all influence outcomes. Protein intake becomes more important as appetite drops, eating less but eating well is the practical version of the guidance. People sometimes ask whether Wegovy at 1mg is effective enough to produce real results, and the evidence suggests meaningful progress is possible at that stage, though the full maintenance dose is where the trial data is strongest. None of this is a reason to doubt the medicine; it is the honest picture of how it works.

If you are weighing up the cost of Wegovy treatment as part of your planning, factoring in the full titration journey (not just the first month) gives a more realistic view of what private treatment involves. There is no shortcut to maintenance dose, and no reputable service will suggest otherwise.

If you are ready to find out whether Wegovy is clinically suitable for you, start your free consultation with our prescribers, who review every application the same day.